B
Borealis Biosciences
Borealis Biosciences was established on the belief that recent scientific and translational advancements are unlocking the potential of RNA medicines to treat kidney diseases and more
About Borealis Biosciences
Borealis Biosciences is a Vancouver-based biotechnology firm focused on creating next-generation RNA-based medicines to treat kidney diseases. The company launched in August 2024, emerging from stealth with $150 million in a combined Series A financing and strategic research collaboration funding. The primary investors are founding investor Versant Ventures and the pharmaceutical company Novartis AG.
The company's genesis is directly linked to Chinook Therapeutics, a successful kidney disease company also founded by Versant Ventures in 2019 and later acquired by Novartis in 2023 for up to $3.5 billion. Following the acquisition, Novartis and Versant collaborated to establish Borealis as an independent entity, built around key members of Chinook's Vancouver-based research team. This strategic formation involved Novartis divesting the former 23,000-square-foot Chinook operating site in Vancouver, transferring certain employees, and investing in the new company. The initial team of over 25 individuals consists of experienced drug developers with deep expertise in kidney disease, RNA therapeutics, and translational data science.
Borealis' business model is centered on the discovery and development of RNA therapeutics for kidney diseases that have been difficult to address with traditional small molecules or biologics. The company utilizes advanced approaches in patient stratification, genetically defined targets, and RNA chemistry to deliver therapeutic payloads to specific kidney cell types. Its revenue and growth are supported by a strategic collaboration with Novartis. As part of this agreement, Novartis has committed up to $100 million in upfront and near-term research funding and holds an option to acquire two future development-ready programs from Borealis for a total consideration of up to $750 million, including milestones.
The company's core product focus is on xRNA, a technology platform that can target the body's natural mRNA to modulate the production of proteins that cause disease. Borealis aims to address significant unmet needs for patients with various kidney diseases, including IgA nephropathy, by targeting causal disease drivers that have previously been considered undruggable. The company operates from a state-of-the-art facility in Vancouver, which includes labs for molecular and cellular biology, chemistry, and analytical capabilities, providing a robust foundation for its research and development objectives.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2024
- Headquarters
- Vancouver, Canada
- Employees
- 54
- Open positions
- 2
- Dealroom signal
- 27.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS
- Business model
- Manufacturing
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Dec 2024 | $30M | $750M | Westlake Village BioPartners | ↗ |
| SERIES AOther financing | Aug 2024 | $150M | $600M | Versant Ventures · Novartis | ↗ |
Growth signals
Latest recorded traffic for Borealis Biosciences is 860 monthly website visits, down 42.7% over the last three months.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Borealis Biosciences in the Vancouver ecosystem
The Borealis Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Versant Ventures
Novartis
Westlake Village BioPartners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Borealis Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Borealis Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






